A double-blind, placebo-controlled, parallel group study was performed to compare the analgesic efficacy of @entity3522 (25, 50, or 100 mg) with that of @entity117 (650 mg), or placebo. Two hundred fifty-five inpatients with severe @entity158 were randomly assigned to receive a single oral dose of one of the four active treatments or placebo. @entity1337 was assessed over an 8-hour period. Treatments were compared on the basis of standard scales for @entity158 intensity and relief and a number of derived variables based on these data, as well as two global ratings of the study medication. All active treatments were effective analgesics statistically superior to placebo for many hourly and summary measures, including the global ratings. @entity3522 (50 and 100 mg) was statistically significantly superior to @entity117 at half-hour and for many other hourly scores from hour 3 on. The 4- and 8-hour sum of the @entity158 intensity difference and total @entity158 relief scores reflected the superiority of @entity3522 to @entity117 . In addition, the 100-mg dose was significantly more efficacious than the 25-mg dose of @entity3522 . The probability of obtaining onset was significantly better for all active treatments than for placebo; however, the median onset times were similar for all treatments. The duration of effect, as measured by mean @entity158 intensity difference and relief scores, was better for @entity3522 than @entity117 , and these differences were significant for the 50- and 100-mg doses. The probability of @entity158 returning to baseline was significantly less for the @entity3522 groups than for placebo or @entity117 groups. In addition, significantly fewer @entity1 treated with @entity3522 (25, 50, or 100 mg) or @entity117 (650 mg) required remedication during the 8-hour study period as compared with those treated with placebo. @entity3522 is an effective analgesic in the range of @entity117 (650 mg) at the 25-mg dose and superior in efficacy and longer lasting than @entity117 at the 50- and 100-mg doses. The onset of @entity1337 was similar for @entity117 and @entity3522 .

Onset and duration of @entity1337 of XXXX in the treatment of @entity158 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac', 'Diclofenac potassium', 'diclofenac potassium'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia', 'Analgesia'] @entity158 :: ('MESH:D010146', 'Disease') :: ['postepisiotomy pain', 'pain']
@entity3522 :: (MESH:D004008,Chemical) :: ['diclofenac potassium']
